Literature DB >> 8643255

Long-term follow-up of Graves ophthalmopathy in an incidence cohort.

G B Bartley1, V Fatourechi, E F Kadrmas, S J Jacobsen, D M Ilstrup, J A Garrity, C A Gorman.   

Abstract

PURPOSE: To provide long-term follow-up data on patients with Graves ophthalmopathy in an incidence cohort of 120 patients.
METHODS: Data were obtained from a comprehensive review of each patient's community medical record, a follow-up survey, or both.
RESULTS: The median interval between the initial ophthalmic examination and most recent follow-up was 9.8 years (range, 64 days to 17.4 years). Follow-up of more than 5 years was available for 96 patients (80.0 percent), whereas follow-up exceeding 10 years was achieved for 59 patients (49.2 percent). Persistent visual loss from optic neuropathy occurred in two eyes, with final visual acuities of 20/30 and 20/60, respectively. None of the patients reported deterioration of vision attributable to Graves ophthalmopathy in the interval since their last ophthalmic examination at the authors' institution. Two patients (2.2 percent) had constant diplopia, but it was correctable with spectacles (prisms) in each case. Nearly one third of respondents had had ocular discomfort during the preceding 4 weeks; the most frequent cause in 72 percent of patients was dry eyes. Among the respondents to the survey, 60.5 percent believed that the appearance of their eyes had not returned to what it had been before the development of thyroid disease, 51.6 percent thought that their eyes appeared abnormal, and 37.9 percent were dissatisfied with the appearance of their eyes.
CONCLUSIONS: Although with treatment few patients have long-term functional impairment from Graves ophthalmopathy, more than one third of patients are dissatisfied with their ultimate appearance. The psychologic, aesthetic, economic, and social sequelae of the disorder require further definition by formal outcomes studies.

Entities:  

Mesh:

Year:  1996        PMID: 8643255     DOI: 10.1016/s0161-6420(96)30579-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  25 in total

Review 1.  Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?

Authors:  P Anagnostis; K Boboridis; F Adamidou; M Kita
Journal:  J Endocrinol Invest       Date:  2016-09-23       Impact factor: 4.256

2.  Quality of life in patients with Graves ophthalmopathy.

Authors:  R Patrick Yeatts
Journal:  Trans Am Ophthalmol Soc       Date:  2005

3.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

4.  Reactivation of thyroid-associated orbitopathy after cataract surgery.

Authors:  Joseph M Shadpour; Ravi M Menghani; Raymond S Douglas; Robert A Goldberg; Angelo Tsirbas
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

5.  Graves opthalmopathy and psychoendocrinopathies.

Authors:  Asaad A Ghanem; Mostafa A Amr; Lamiaa F Araafa
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

6.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

7.  Thyroid associated orbitopathy following periocular surgery.

Authors:  Sang June Kim; Byoung Jin Kim; Ha Bum Lee; Angelo Tsirbas; Michael Kazim
Journal:  Korean J Ophthalmol       Date:  2006-06

8.  Increased generation of fibrocytes in thyroid-associated ophthalmopathy.

Authors:  Raymond S Douglas; Nikoo F Afifiyan; Catherine J Hwang; Kelvin Chong; Uzma Haider; Patrick Richards; Andrew G Gianoukakis; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2009-11-06       Impact factor: 5.958

9.  Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL.

Authors:  C B Terwee; M N Gerding; F W Dekker; M F Prummel; W M Wiersinga
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

10.  Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Authors:  Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.